Analysis of United States Drug Patent 10,407,393: Etrasimod
What is Patent 10,407,393 and What Does It Protect?
United States Patent 10,407,393, granted on September 10, 2019, to Arena Pharmaceuticals, Inc., covers Etrasimod, a sphingosine-1-phosphate (S1P) receptor modulator. The patent's primary claims are directed towards specific crystalline forms of etrasimod, particularly those exhibiting desirable pharmaceutical properties such as improved stability and processability. These crystalline forms are critical for the effective formulation and delivery of the active pharmaceutical ingredient (API).
The patent details the synthesis of etrasimod and identifies several specific crystalline polymorphs. Key claims focus on:
- Claim 1: A specific crystalline form of 4-amino-5-(4-phenoxyphenyl)-3-(3-(trifluoromethyl)phenyl)-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxamide, characterized by specific X-ray powder diffraction (XRPD) peaks. This claim defines a particular solid-state form of the etrasimod molecule.
- Claim 11: A pharmaceutical composition comprising the crystalline form of etrasimod described in Claim 1 and a pharmaceutically acceptable carrier. This broadens the protection to include the API formulated for therapeutic use.
- Claim 13: A method of treating an S1P-mediated disease comprising administering a therapeutically effective amount of the pharmaceutical composition of Claim 11. This claim extends protection to the therapeutic application of the patented compound and its formulations.
The patent describes etrasimod as a modulator of S1P receptors 1, 4, and 5. S1P receptor modulation is a recognized mechanism for treating immune-mediated inflammatory diseases by influencing lymphocyte trafficking. Etrasimod's specific binding profile and its ability to reduce lymphocyte counts without significantly impacting other immune cell populations are central to its therapeutic rationale [1].
What is the Therapeutic Application of Etrasimod?
Etrasimod is developed for the treatment of immune-mediated inflammatory diseases. Its mechanism of action involves selectively modulating S1P receptors, leading to the sequestration of lymphocytes in secondary lymphoid organs. This reduces the number of circulating lymphocytes that can migrate to sites of inflammation, thereby mitigating autoimmune responses.
The primary indication for which etrasimod has been developed and approved is ulcerative colitis (UC). In June 2023, the U.S. Food and Drug Administration (FDA) approved etrasimod (marketed as Velsipity) for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more conventional therapies [2].
Beyond ulcerative colitis, etrasimod is also being investigated for other immune-mediated conditions, including:
- Crohn's disease: Another inflammatory bowel disease.
- Atopic dermatitis: A chronic inflammatory skin disease.
- Rheumatoid arthritis: A chronic inflammatory disorder affecting joints.
The selective S1P receptor modulation profile of etrasimod differentiates it from other S1P modulators, such as fingolimod, which also targets S1P receptor subtypes 1, 3, 4, and 5. Etrasimod's specific affinity for S1P receptors 1, 4, and 5 is designed to achieve therapeutic benefits while potentially minimizing certain side effects associated with broader S1P receptor engagement [3].
What is the Patent Landscape Surrounding Etrasimod?
The patent landscape for etrasimod is characterized by a combination of compound patents, crystalline form patents, formulation patents, and method of use patents. Arena Pharmaceuticals, Inc. (now part of Pfizer) has established a robust patent portfolio to protect etrasimod throughout its lifecycle.
Key Patent Families and Exclusivity
The foundational patent for the etrasimod compound itself is likely to have expired or be nearing expiration in the near future, based on typical patent terms. However, the granted patent 10,407,393, along with other patents covering specific crystalline forms and formulations, extends the period of market exclusivity.
The patent landscape includes:
- Composition of Matter Patents: These are the most fundamental patents, protecting the etrasimod molecule itself. The earliest such patents would have been filed in the early 2000s.
- Polymorph Patents (e.g., 10,407,393): Patents covering specific crystalline forms are crucial for extending exclusivity. Different polymorphs can offer advantages in manufacturing, stability, and bioavailability. Patent 10,407,393 specifically claims a desirable crystalline form.
- Formulation Patents: These patents cover specific drug product compositions, including excipients, dosages, and delivery systems, which can provide additional layers of protection.
- Method of Use Patents: These patents protect specific therapeutic applications of etrasimod, such as its use in treating ulcerative colitis, Crohn's disease, or other conditions.
The interplay of these patent types dictates the overall exclusivity period for etrasimod. The U.S. patent system typically grants a 20-year term from the filing date, with potential for extensions through the Patent Term Restoration Act (PTRA) to compensate for regulatory review delays.
Potential Challenges and Generic Entry
The expiry of composition of matter patents opens the door for generic manufacturers to seek approval for their own versions of etrasimod. However, the existence of later-expiring patents, such as polymorph and formulation patents, can act as significant barriers to generic entry.
Generic companies must navigate these patents by:
- Developing Non-Infringing Polymorphs: If a generic manufacturer can demonstrate a crystalline form of etrasimod that does not infringe on the claims of patent 10,407,393 or other polymorph patents, they may be able to proceed.
- Challenging Patent Validity: Generic companies may attempt to invalidate existing patents through litigation.
- Designing Around Formulations: Developing alternative formulations that do not infringe on existing patent claims.
The U.S. market exclusivity for Velsipity (etrasimod) is influenced by the expiration dates of key patents. While specific patent expiry dates can be complex to track due to continuations, reissues, and potential litigation outcomes, patent 10,407,393 provides a layer of protection for a specific crystalline form.
What is the Commercial Significance of Etrasimod and its Patents?
Etrasimod represents a significant development in the treatment of immune-mediated inflammatory diseases, particularly ulcerative colitis. Its novel mechanism of action and favorable safety profile, as demonstrated in clinical trials and post-market surveillance, position it as a key therapeutic option.
The commercial success of etrasimod is directly tied to the strength and breadth of its patent portfolio. Patent 10,407,393, by protecting a specific, likely advantageous crystalline form, contributes to this exclusivity by:
- Securing Market Share: Preventing competitors from launching generic versions of etrasimod in the same stable, usable crystalline form.
- Maximizing Return on Investment: Allowing Pfizer (the current owner) to recoup substantial R&D investments made in developing etrasimod.
- Incentivizing Future Innovation: The protection afforded by such patents encourages continued investment in drug discovery and development.
The market for ulcerative colitis treatments is substantial and growing. Estimates place the global UC market in the tens of billions of dollars, with a significant portion of that in the United States. Etrasimod's approval for UC positions it to capture a meaningful share of this market.
Competitive Landscape
Etrasimod competes with a range of existing and emerging therapies for UC, including:
- Aminosalicylates (5-ASAs): Mesalamine, sulfasalazine.
- Corticosteroids: Prednisone, budesonide.
- Immunomodulators: Azathioprine, 6-mercaptopurine, methotrexate.
- Biologics: TNF inhibitors (infliximab, adalimumab, golimumab), vedolizumab (integrin inhibitor), ustekinumab (IL-12/23 inhibitor).
- Other S1P Modulators: Ozanimod (Zeposia), siponimod (Mayzent).
Etrasimod's differentiated S1P receptor profile and oral administration offer potential advantages over some of these treatment options, particularly regarding convenience and a distinct efficacy/safety balance.
The commercial significance of patent 10,407,393 is therefore substantial, as it underpins the proprietary nature of the etrasimod API in a form suitable for commercial drug production and sale. This allows for premium pricing and protects revenue streams against early-stage generic competition, particularly for the specifically claimed crystalline form.
How Does Patent 10,407,393 Interact with Regulatory Exclusivity?
Patent 10,407,393, like other U.S. drug patents, interacts with regulatory exclusivity granted by the FDA to provide market protection for etrasimod. Regulatory exclusivities are granted based on the type of drug and the regulatory pathway used for approval, independent of patent rights.
Key FDA exclusivities that may apply to etrasimod include:
- New Chemical Entity (NCE) Exclusivity: Typically five years for a new drug that contains no active moiety that has been approved in any other application previously submitted to the FDA.
- Orphan Drug Exclusivity (ODE): Seven years for drugs designated as orphan drugs, granted for the treatment of rare diseases.
- Patent Dance and Hatch-Waxman Act: This legislation governs the interplay between patents and generic drug approvals. When a drug sponsor submits an Abbreviated New Drug Application (ANDA) for a generic version, they must certify that the patent(s) listed in the FDA's Orange Book are either invalid, expired, or will not be infringed by the proposed generic product.
Patent 10,407,393 is listed in the FDA's Orange Book [4]. Its listing signifies that it is a relevant patent protecting etrasimod. Generic manufacturers seeking to launch etrasimod must address this patent, either by waiting for its expiration, challenging its validity, or demonstrating a non-infringing process or product.
Interplay with Patent Term Extension (PTE)
In addition to the 20-year patent term, patent holders can apply for Patent Term Extension (PTE) under the Hatch-Waxman Act to recover some of the patent term lost during the FDA's regulatory review period. The PTE is calculated based on the time spent in clinical trials and the FDA review process. The effective patent life of etrasimod is thus a combination of its original patent term, any PTE granted, and the term of later-expiring patents like 10,407,393, as well as the overlapping regulatory exclusivities.
The duration of protection afforded by patent 10,407,393, combined with potential PTE and regulatory exclusivities, is critical for determining the timeline for potential generic competition. The specific claims of patent 10,407,393, relating to a particular crystalline form, provide a distinct basis for exclusivity that can extend beyond the expiry of the original compound patent. This dual protection strategy is common in the pharmaceutical industry to maximize market exclusivity.
Key Takeaways
- United States Patent 10,407,393 protects a specific crystalline form of etrasimod, a sphingosine-1-phosphate (S1P) receptor modulator.
- Etrasimod is approved for moderately to severely active ulcerative colitis and is under investigation for other immune-mediated inflammatory diseases.
- The patent landscape for etrasimod includes compound, polymorph, formulation, and method of use patents, creating multiple layers of market protection.
- Patent 10,407,393 plays a critical role in extending market exclusivity for etrasimod by protecting a specific solid-state form of the API.
- The commercial significance of this patent is tied to etrasimod's success in the substantial ulcerative colitis market, where it competes with numerous established and emerging therapies.
- Patent 10,407,393 interacts with FDA regulatory exclusivities and potential patent term extensions to define the overall period of market protection against generic entry.
Frequently Asked Questions
What is the precise chemical name of the compound protected by patent 10,407,393?
The compound is 4-amino-5-(4-phenoxyphenyl)-3-(3-(trifluoromethyl)phenyl)-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxamide.
What are the key S1P receptor subtypes that etrasimod modulates according to patent 10,407,393?
The patent indicates modulation of S1P receptors 1, 4, and 5.
What specific advantages does the crystalline form claimed in patent 10,407,393 offer?
The patent suggests advantages in stability and processability, which are critical for pharmaceutical manufacturing and formulation.
Does patent 10,407,393 cover the therapeutic use of etrasimod in ulcerative colitis?
While the patent does include claims for methods of treating S1P-mediated diseases (which would encompass ulcerative colitis), specific method of use patents may also exist that more directly address this indication.
How long is the patent term for United States Patent 10,407,393?
The standard patent term is 20 years from the filing date. However, this can be extended through Patent Term Extension (PTE) for pharmaceutical patents, and its effective lifespan is also influenced by overlapping regulatory exclusivities and potential litigation.
Citations
[1] Arena Pharmaceuticals, Inc. (2019). U.S. Patent 10,407,393. United States Patent and Trademark Office.
[2] U.S. Food & Drug Administration. (2023, June 21). FDA approves Velsipity (etrasimod) for moderately to severely active ulcerative colitis. FDA News Release.
[3] Hu, B., et al. (2022). Etrasimod, a novel oral S1P receptor modulator, in ulcerative colitis: A randomized, double-blind, placebo-controlled, Phase 2b trial. Gastroenterology, 162(1), 109-119.e5.
[4] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA website]
